Capecitabine and Mitomycin C for Colorectal Cancer
Author Information
Author(s): Chong G, Cunningham D
Primary Institution: Royal Marsden Hospital
Hypothesis
Can the combination of capecitabine and mitomycin C be an effective treatment for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan?
Conclusion
The combination of capecitabine and mitomycin C shows a response rate of 15.4% in patients previously treated for colorectal cancer.
Supporting Evidence
- The study shows a 15.4% response rate for the combination of MMC and capecitabine.
- Previous studies indicated limited efficacy of capecitabine alone for 5FU-refractory patients.
- Preclinical data suggest that mitomycin C may enhance the effectiveness of capecitabine.
Takeaway
This study suggests that using capecitabine with another drug called mitomycin C can help some patients with a tough type of cancer.
Methodology
The study involved a single-arm trial assessing the efficacy of capecitabine and mitomycin C in patients with advanced colorectal cancer.
Limitations
The results may not apply to patients who have received other treatments like oxaliplatin or targeted agents.
Participant Demographics
Of the 36 patients, 31 had liver metastases, and 8 had their primary tumor in situ.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website